2nd in the country! Howson's "Apple Acid Scone Capsule" is about to be approved

(Source: NMPA)the world's 1 billion-class anti-cancer drugthe ealitic schoniten capsule (product name: Sotan/Sutent) was developed by Pfizer and approved by the FDA in January 2006 and approved in the European Union in June of that yearThe drug is a small molecule multi-target receptor tyrosine kinase (RTKs) inhibitor with multiple effects that inhibit tumor angiogenesis and antitumor cell production and metastasis, including PDGFR (PDGFR alpha and PDGFR beta)) VEGFR (VEGFR1, VEGFR2, VEGFR3), FLT-3, CSF-1R, Kit and ret, clinically mainly used in the treatment of patients with gastrointestinal interlics, renal cell carcinoma and pancreatic neuroendocrine tumorsin the United States, sconetinib is a frequently prescribed drug in an oral drug approved for advanced kidney cancerTo date, more than 250,000 patients worldwide have received sconetinib treatmentBut in recent years, Schonitini's annual sales have been falling, falling below $1 billion for the first time since 2010, when it reached $1,066 million, peaking at $1.236 billion in 2012, according to global best-selling drug statisticsSeptember 2007, Schonitinib was approved by NMPA in China, the dosage form is capsule, specifications of 125mg, 37.5mg, 50mg, 25mg fourDomestic market, although in January 2020 before the approval of the first imitation of stone medicine, only Pfizer's original research Schonitinib listed, but its performance in the market has been tepid, according to domestic sample hospital statistics, from 2012-2018 sales in the coming year, the product is not warm, sales in more than 50 million yuan, has not yet entered the ranks of domestic heavyweight products2018, Schonitini was included in the health insurance after negotiations, and the current national winning bid of 12.5mg is 155 yuan, a drop of nearly 65% from the pre-negotiation winning bid of about 438.16 yuanDomestic sales are expected to rise in the futurestone medicine took the first imitationSconetini domestic compound patent will expire in 2021, according to insight database shows that the stone medicine Oyi, Koren, Qilu, Zhengda Tianqing, Howson are in the new 4 categories to submit the listing application of Shumitini(source: Insight database)January 2020, the apple acid sconecapsule capsule developed by Theo-Italian, with a specification of 12.5mg, has been issued by the NMPA for the drug registration approval, the first approved generic drug for the variety in China, and as a result of the consistent evaluation(Source: Company Announcement), who thought it would be the second to take generics, now looks like Howson is outright.